Table 1

Clinical characteristics of ACPA-negative and ACPA-positive patients in the symptomatic phase preceding clinical arthritis

All patients
ACPA negative (n=37)ACPA positive (n=30)p Value
Symptoms at symptom onset
Symptom onset
 Acute (<1 week)8 (22)8 (27)0.53
 Gradual26 (70)16 (55)
 Intermittent3 (8)5 (17)
Symptoms started with*
 Pain34 (92)29 (97)0.41
 Stiffness26 (70)17 (57)0.25
 Loss of function16 (43)10 (33)0.41
Localisation affected joints
 Small joints hand/feet27 (73)21 (70)0.18
 Large joints5 (14)1 (3)
 Both5 (14)8 (27)
Localisation affected joints
 Upper extremities29 (78)15 (50)0.014
 Lower extremities5 (14)4 (13)
 Both3 (8)11 (37)
Localisation affected joints
 Symmetric22 (60)22 (73)0.23
Presentation with arthralgia
Family history of RA13 (35)11 (37)0.90
Symptoms determining inclusion in the cohort
 Inflammatory type of symptoms14 (39)18 (60)0.089
 Morning stiffness ≥60 min9 (25)2 (7)
 Both13 (36)10 (33)
Physical examination
 68 TJC, mean±SD9±85±30.007†
 Difficulties making a fist16 (43)3 (11)0.004†
 Squeeze test
  Positive for both MTP and MCP joints8 (22)4 (14)0.48
  Positive for MCP joints only11 (31)7 (24)
  Positive for MTP joints only4 (11)2 (7)
  Negative for both13 (36)16 (55)
HAQ score, mean±SD0.8±0.60.7±0.60.57
  • All values are indicated as n (%), unless indicated otherwise.

  • Missings were as follows: symptom onset (1), symptoms determining inclusion in the cohort (1), difficulties making a fist (1), squeeze test (2), HAQ score (2).

  • *Multiple answers could be given, so the percentages can add up to >100%.

  • †Significant after correction for multiple testing.

  • ACPA, anticitrullinated protein antibodies; HAQ, health assessment questionnaire; MCP, metacarpophalangeal; MTP, metatarsophalangeal; RA, rheumatoid arthritis; TJC, tender joint count.